TG THERAPEUTICS, INC. (TGTX) Current Ratio
- Current ratio · latest quarter: Value 4.27×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.27× | Current assets / current liabilities. $1.15B ÷ $268.49M ≈ 4.27× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.15B USD | Assets, Current |
| Current obligations | 268.49M USD | Liabilities, Current |
| Cash and equivalents | 482.57M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 401.56M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 147.97M USD | Inventory, Net |
| Payables | (m) | |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.15B | $268.49M | $482.57M | (m) | $401.56M | $147.97M | (m) | (m) | 4.27× |
| 2026-03-31 | $1.09B | $187.11M | $442.21M | (m) | $392.05M | $129.03M | (m) | (m) | 5.81× |
| 2025-12-31 | $630.76M | $153.76M | $79.15M | (m) | $305.63M | $125.59M | (m) | (m) | 4.10× |
| 2025-09-30 | $599.76M | $156.81M | $74.08M | (m) | $265.38M | $146.95M | (m) | (m) | 3.82× |
| 2025-06-30 | $663.96M | $171.89M | $129.13M | (m) | $231.52M | $155.20M | (m) | (m) | 3.86× |
| 2025-03-31 | $644.51M | $160.21M | $132.14M | (m) | $190.12M | $157.76M | (m) | (m) | 4.02× |
| 2024-12-31 | $566.36M | $90.68M | $179.89M | (m) | $129.19M | $110.46M | (m) | (m) | 6.25× |
| 2024-09-30 | $574.07M | $125.11M | $195.82M | (m) | $115.73M | $84.67M | (m) | (m) | 4.59× |
| 2024-06-30 | $389.15M | $108.66M | $82.91M | (m) | $83.61M | $81.24M | (m) | (m) | 3.58× |
| 2024-03-31 | $360.58M | $99.68M | $75.48M | (m) | $64.98M | $77.72M | (m) | (m) | 3.62× |
| 2023-12-31 | $317.94M | $53.72M | $92.93M | (m) | $51.09M | $39.82M | (m) | (m) | 5.92× |
| 2023-09-30 | $319.11M | $57.68M | $150.90M | (m) | (m) | $33.55M | (m) | $0.00 | 5.53× |
| 2023-06-30 | $208.57M | $72.67M | $97.01M | (m) | (m) | $30.23M | (m) | (m) | 2.87× |
| 2023-03-31 | $184.78M | $63.08M | $61.47M | (m) | (m) | $27.22M | (m) | (m) | 2.93× |
| 2022-12-31 | $168.27M | $53.20M | $102.30M | (m) | $0.00 | $0.00 | (m) | (m) | 3.16× |
| 2022-09-30 | $182.92M | $36.45M | $109.86M | (m) | (m) | (m) | (m) | (m) | 5.02× |
| 2022-06-30 | $202.56M | $43.33M | $147.07M | (m) | (m) | (m) | (m) | (m) | 4.68× |
| 2022-03-31 | $242.22M | $54.66M | $185.68M | (m) | (m) | (m) | (m) | (m) | 4.43× |
| 2021-12-31 | $330.96M | $65.38M | $298.89M | (m) | (m) | (m) | (m) | $975.00K | 5.06× |
| 2021-09-30 | $371.78M | $87.66M | $326.51M | (m) | (m) | (m) | (m) | $16.00M | 4.24× |
| 2021-06-30 | $455.07M | $87.55M | $401.71M | (m) | (m) | (m) | (m) | $23.16M | 5.20× |
| 2021-03-31 | $535.01M | $92.49M | $471.51M | (m) | (m) | (m) | (m) | $30.13M | 5.78× |
| 2020-12-31 | $611.74M | $87.55M | $553.44M | (m) | (m) | (m) | (m) | $22.18M | 6.99× |
| 2020-09-30 | $260.33M | $77.67M | $254.15M | (m) | (m) | (m) | (m) | $14.59M | 3.35× |
| 2020-06-30 | $280.94M | $67.54M | $260.51M | (m) | (m) | (m) | (m) | $7.20M | 4.16× |
| 2020-03-31 | $88.02M | $63.12M | $52.05M | (m) | (m) | (m) | (m) | (m) | 1.39× |
| 2019-12-31 | $149.15M | $84.45M | $112.64M | (m) | (m) | (m) | (m) | $0.00 | 1.77× |
| 2019-09-30 | $80.36M | $80.20M | $44.67M | (m) | (m) | (m) | (m) | $0.00 | 1.00× |
| 2019-06-30 | $94.44M | $55.97M | $57.23M | (m) | (m) | (m) | (m) | $0.00 | 1.69× |
| 2019-03-31 | $105.06M | $60.94M | $64.35M | (m) | (m) | (m) | (m) | $0.00 | 1.72× |
| 2018-12-31 | $79.03M | $38.85M | $41.96M | (m) | (m) | (m) | (m) | (m) | 2.03× |
| 2018-09-30 | $109.74M | $40.24M | $70.72M | (m) | (m) | (m) | (m) | (m) | 2.73× |
| 2018-06-30 | $136.04M | $36.94M | $105.67M | (m) | (m) | (m) | (m) | (m) | 3.68× |
| 2018-03-31 | $116.96M | $33.34M | $82.90M | (m) | (m) | (m) | (m) | (m) | 3.51× |
| 2017-12-31 | $93.32M | $27.96M | $56.72M | (m) | (m) | (m) | (m) | (m) | 3.34× |
| 2017-09-30 | $97.66M | $19.79M | $91.84M | (m) | (m) | (m) | (m) | (m) | 4.93× |
| 2017-06-30 | $97.04M | $20.76M | $77.60M | (m) | (m) | (m) | (m) | (m) | 4.67× |
| 2017-03-31 | $118.96M | $19.73M | $95.64M | (m) | (m) | (m) | (m) | (m) | 6.03× |
| 2016-12-31 | $50.86M | $16.88M | $25.03M | (m) | (m) | (m) | (m) | (m) | 3.01× |
| 2016-09-30 | $71.33M | $16.88M | $29.16M | (m) | (m) | (m) | (m) | (m) | 4.23× |
| 2016-06-30 | $69.55M | $14.12M | $28.58M | (m) | (m) | (m) | (m) | (m) | 4.93× |
| 2016-03-31 | $70.58M | $8.89M | $36.48M | (m) | (m) | (m) | (m) | (m) | 7.94× |
| 2015-12-31 | $86.87M | $10.53M | $55.06M | (m) | (m) | (m) | (m) | (m) | 8.25× |
| 2015-09-30 | $104.73M | $9.69M | $65.46M | (m) | (m) | (m) | (m) | (m) | 10.81× |
| 2015-06-30 | $103.73M | $9.21M | $60.30M | (m) | (m) | (m) | (m) | (m) | 11.26× |
| 2015-03-31 | $115.74M | $9.55M | $86.00M | (m) | (m) | (m) | (m) | (m) | 12.12× |
| 2014-12-31 | $85.22M | $5.12M | $55.71M | (m) | (m) | (m) | (m) | (m) | 16.64× |
| 2014-09-30 | $76.67M | $8.90M | $53.23M | (m) | (m) | (m) | (m) | (m) | 8.61× |
| 2014-06-30 | $49.29M | $2.61M | $37.08M | (m) | (m) | (m) | (m) | (m) | 18.91× |
| 2014-03-31 | $56.29M | $1.99M | $49.60M | (m) | (m) | (m) | (m) | (m) | 28.30× |
| 2013-12-31 | $42.30M | $6.32M | $40.49M | (m) | (m) | (m) | (m) | (m) | 6.70× |
| 2013-09-30 | $50.61M | $5.68M | $50.18M | (m) | (m) | (m) | (m) | (m) | 8.91× |
| 2013-06-30 | $14.17M | $3.47M | $13.42M | (m) | (m) | (m) | (m) | (m) | 4.09× |
| 2013-03-31 | $17.79M | $2.47M | $15.19M | (m) | (m) | (m) | (m) | (m) | 7.19× |
| 2012-12-31 | $18.48M | $2.22M | $16.46M | (m) | (m) | (m) | (m) | (m) | 8.34× |
| 2012-09-30 | $19.16M | $2.96M | $17.37M | (m) | (m) | (m) | (m) | (m) | 6.48× |
| 2012-06-30 | $20.46M | $2.35M | $20.37M | (m) | (m) | (m) | (m) | (m) | 8.71× |
| 2012-03-31 | $21.00M | $1.22M | $20.92M | (m) | (m) | (m) | (m) | (m) | 17.19× |
| 2011-12-31 | $9.84M | $1.61M | $9.75M | (m) | (m) | (m) | (m) | (m) | 6.12× |
| 2011-09-30 | $313.04K | $1.52M | $212.28K | (m) | (m) | (m) | (m) | (m) | 0.21× |
| 2011-06-30 | $609.33K | $3.78M | $492.51K | (m) | (m) | (m) | (m) | (m) | 0.16× |
| 2010-12-31 | $869.18K | $3.29M | $478.67K | (m) | (m) | (m) | (m) | (m) | 0.26× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |